COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

COL.AU

18.72

+1.85%↑

CAR.AU

36.78

-0.14%↓

WOR.AU

14.51

-1.96%↓

RSG.AU

0.67

+3.08%↑

MMS.AU

16.14

+0.75%↑

Kodu・Aktsiate loetelu・CSL Ltd

CSL Ltd

Suletud

Sektor

303.69 0.59

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

303.19

Max

304.27

Põhinäitajad
By Trading Economics
Sissetulek	1.9B
Müük	8.1B
Aktsiakasum	4.159
Kasumimarginaal	23.606

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+6.31 upside

Turustatistika
By TradingEconomics
Turukapital	-686M 148B
Eelmine avamishind	303.1
Eelmine sulgemishind	303.69

Uudiste sentiment

By Acuity

50%

92 / 382 Pingereas Industrials

CSL Ltd Graafik

Seotud uudised

12. aug 2024, 23:23 UTC

Tulu

CSL Annual Profit Rises by 20% on Immunoglobulins Growth -- Update

12. aug 2024, 22:49 UTC

Tulu

CSL Annual Profit Rises by 20%, Forecasts Fiscal Year 2025 Underlying Earnings Growth

12. veebr 2024, 22:16 UTC

Tulu

CSL Says 1st Half Profit Rises, Boosts Dividend -- Update

12. veebr 2024, 22:00 UTC

Tulu

CSL Says 1st Half Profit Rises, Boosts Dividend

13. aug 2024, 00:33 UTC

Market Talk

CSL Profit Outlook Looks Weaker Than Expected -- Market Talk

12. aug 2024, 22:34 UTC

Tulu

CSL Annual Profit Rises by 20%, Forecasts FY 2025 Underlying Earnings Growth

12. aug 2024, 22:18 UTC

Tulu

CSL Expects FY2025 Revenue Growth of Roughly 5%-7% at Constant Currency

12. aug 2024, 22:18 UTC

Tulu

CSL: Conditions for Seqirus Remain Challenging, But Unit Expected to Outperform Market

12. aug 2024, 22:17 UTC

Tulu

CSL: Has a Number of Efficiency Initiatives Underway in Plasma Collections, Manufacturing Operations

12. aug 2024, 22:16 UTC

Tulu

CSL: Momentum in Behring Seen Underpinned by Strong Patient Demand in Immunoglobulins

12. aug 2024, 22:15 UTC

Tulu

CSL: Remains Confident in Medium-Term Double-Digit Earnings Growth Target

12. aug 2024, 22:14 UTC

Tulu

CSL: Vifor Continues to Grow Iron Volume in Europe Despite Generic Entrants

12. aug 2024, 22:13 UTC

Tulu

CSL Expects FY2025 Underlying Profit Up Between 10%-13% on Constant Currency Basis

12. aug 2024, 22:13 UTC

Tulu

CSL Expects FY2025 Underlying Profit Between US$3.2 Billion-US$3.3 Billion

12. aug 2024, 22:11 UTC

Tulu

CSL: Outlook for Behring Positive But Competitive Pressures Increased Recently

12. aug 2024, 22:10 UTC

Tulu

CSL FY Underlying Profit Up 15% on Constant Currency Basis to US$3.01 Billion

12. aug 2024, 22:09 UTC

Tulu

CSL FY Revenue US$14.80 Billion, Up 11% On-Year

12. aug 2024, 22:08 UTC

Tulu

CSL FY Underlying Profit US$2.91 Billion, Up 11% On-Year

12. aug 2024, 22:07 UTC

Tulu

CSL FY Net Profit US$2.64 Billion, Up 20% On-Year

12. aug 2024, 22:07 UTC

Tulu

CSL Final Dividend US$1.45/Share

13. veebr 2024, 01:50 UTC

Market Talk

Tulu

CSL Still Confident on Long-Term Value at Vifor Business -- Market Talk

13. veebr 2024, 00:39 UTC

Market Talk

Tulu

UBS Sees Mixed Bag in CSL's Half-Year Results -- Market Talk

12. veebr 2024, 22:01 UTC

Tulu

CSL Says 1H Profit Rises, Boosts Dividend -- Update

12. veebr 2024, 21:45 UTC

Peamised uudised

Tulu

CSL Says 1H Profit Rises, Boosts Dividend

12. veebr 2024, 21:35 UTC

Tulu

CSL Says 1H Result Driven by CSL Behring Unit, Especially Immunoglobulins

12. veebr 2024, 21:33 UTC

Tulu

CSL Anticipates Loss in 2H for Flu-Vaccine Unit Seqirus Due to Seasonality of Business

12. veebr 2024, 21:33 UTC

Tulu

CSL Says FY 2024 Underlying Profit Growth Expected 13%-17% on-Year

12. veebr 2024, 21:32 UTC

Tulu

CSL Says Underlying Profit Expected in Range of US$2.9-US$3.0 Bln at Constant Currency

12. veebr 2024, 21:31 UTC

Tulu

CSL Reaffirms Previous Guidance

12. veebr 2024, 21:30 UTC

Tulu

CSL 1H Underlying Profit Up 13% on Constant Currency Basis

Võrdlus sarnastega

Hinnamuutus

CSL Ltd Prognoos

Hinnasiht

By TipRanks

6.31% tõus

12 kuu keskmine prognoos

Keskmine 323.182 AUD 6.31%

Kõrge 352 AUD

Madal 278 AUD

Põhineb 12 Wall Streeti analüütiku instrumendi CSL Ltd 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

12 ratings

Osta

Hoia

Müü

Põhineb 12 analüütiku instrumendi CSL Ltd aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

92 / 382 Pingereas

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest CSL Ltd

CSL Limited is an Australia-based biotechnology company. The Company is engaged in developing and delivering biotherapies and influenza vaccines that treat people with serious diseases and chronic medical conditions. It offers treatments for people who are living with conditions in immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. The Company operates through two segments: CSL Behring and Seqirus. CSL Behring manufactures, markets, and develops plasma therapies (plasma products and recombinants), conducts early-stage research on plasma and non-plasma therapies, excluding influenza, receives license and royalty income from the commercialization of intellectual property and undertakes the administrative and corporate function required to support the Company. Seqirus segment manufactures and distributes non-plasma biotherapeutic products and develops influenza related products. Its products include PRIVIGEN, IDELVION and AFSTYLA.